When 2019 Rolls Around, Drug Companies Are Planning Price Hikes on Many Medicines

글 내용 전체보기

FDA Gives Merck Thumbs-Up for Two New Indications

글 내용 전체보기

Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018

글 내용 전체보기

After New Year’s, expect more drug pricing fireworks in 2019

글 내용 전체보기

As immuno-oncology heads into 2019, one thing is clear: It’s good to be Merck

글 내용 전체보기

The valsartan carcinogen mess taught pharma a surprise manufacturing lesson. Will 2019 bring more?

글 내용 전체보기

Merck’s Keytruda puts heat on Pfizer, Merck KGaA’s Bavencio with new Merkel cell OK

글 내용 전체보기

AstraZeneca, Merck’s Lynparza plows ahead in ovarian cancer with $1B-plus approval, phase 3 data

글 내용 전체보기

Will pharma’s exodus from consumer health continue into 2019? It sure looks that way

글 내용 전체보기

Can China’s R&D sector shake its reputational issues in 2019?

글 내용 전체보기

Relay Therapeutics bags $400M to ramp up discovery and push into the clinic

글 내용 전체보기

Biopharma braces for Brexit impact amid political upheaval

글 내용 전체보기

Apellis says timeline still on track for stalled eye drug

글 내용 전체보기

Preventing Clumping: How to Keep Proteins Active

글 내용 전체보기

Neurons migrate in the nascent brain as if on rails

글 내용 전체보기

GlaxoSmithKline plc and Pfizer Inc to form new Consumer Healthcare Joint Venture

글 내용 전체보기

길리어드, 스콜라락과 ‘TGFβ 활성 특이적 저해제’ 15억弗 딜

글 내용 전체보기

Progress in Super-Resolution Microscopy

글 내용 전체보기

제약·바이오 대형 기술수출 10건…유한, 최대 계약금

글 내용 전체보기

연성정밀화학, 안과용 원료약 ‘무결점 FDA 실사’ 통과

글 내용 전체보기

겨울철 비타민D로 건강 ‘UP’…썬팩타민 인기

글 내용 전체보기